Resources
44 Results (showing 1 - 10)
Results sorted by posted date (newest first)
Results sorted by posted date (newest first)
Posted 11/17/2023 (updated 3/28/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has published the new resource "Counseling Approaches To Promote Recovery From Problematic Substance Use and Related Issues". This Treatment Improvement Protocol (TIP) provides guidance to counselors, administrators, and supervisors about recovery-oriented services, supports, and care, allowing them to better serve individuals in or seeking recovery from problematic substance use.
Posted 9/29/2023 (updated 3/27/2024)
The 2023 RCORP-Overdose Response Onboarding Packet contains strategies and resources to assist grantees in the implementation of your new Overdose Response (OR) grant. The Onboarding Packet includes tools to support grant-funded activities, along with information on accessing TA.
Posted 9/8/2023 (updated 3/27/2024)
The Substance Abuse and Mental Health Services Administration (SAMHSA) has updated the 2018 document which outlines best practices for implementing and operating recovery housing. Assisting individuals with recovery housing is critical in the journey of recovery and can lead to the improvement of health, reduce overdose risks, and sustain recovery.
Posted 9/4/2023 (updated 3/26/2024)
Two reports are now available from Fors Marsh, a research and communications firm who's reports work to highlight system problems like SUD. The "Road Map for Advancing a Recovery-Ready Nation" report examines recovery research and covers issues such as support services, housing, employment, workforce, stigma, etc. The "2022 Workplace Recovery Survey Report" covers background and understanding recovery in the workplace, policies, culture, experiences, and much more.
Posted 8/18/2023 (updated 3/26/2024)
The National Institute on Drug Abuse (NIDA) Center for the Clinical Trials Network (CCTN) held an event where health care professionals and federal partners discussed xylazine-related testing, treatment, and wound care. As the White House has deemed fentanyl adulterated with xylazine an emerging threat, it is important to identify and adapt to the rapidly changing practices of patient care.
Posted 7/28/2023 (updated 3/26/2024)
Researchers interviewed 20 individuals – clinicians, peer support specialists, cultural practitioners, and others familiar with OUD treatment – in a Minnesota tribal community. The Cascade of Care model measures the quality of outcomes at each stage of treatment, from diagnosis to long-term maintenance, and was first proposed in 1998 as an approach to care for HIV/AIDS.
Posted 7/26/2023 (updated 3/28/2024)
Rural communities are finding innovative ways to combat dual crises: an affordable-housing shortage and the overdose and substance misuse epidemic. This presentation highlighted (1) federally subsidized housing regulations related to affordable housing for residents with a history of SUD and (2) cross-sector approaches to providing housing and support services to residents in recovery.
Posted 7/26/2023 (updated 3/28/2024)
This session covered multiple aspects of establishing and operating recovery housing in rural America, from planning to funding and through staff hiring, development of policies and procedures, and building program support. Dr. Fletcher and co-presenters will discuss outcomes, the impact on families and individuals, and working with communities to address NIMBY and other concerns.
Posted 4/14/2023 (updated 3/27/2024)
Researchers evaluate The Kentucky Access to Recovery Program (KATR), which provides services to individuals recovering from opioid use in several counties in Eastern Kentucky, and conclude KATR demonstrates a potentially effective strategy for increasing health-related social services in rural areas.
Posted 3/14/2023 (updated 3/27/2024)
Xylazine is a non-opioid that is approved for animals, and not FDA-approved for humans. New York State's Department of Health provides information on what it is, sources and trends, effects, why people use it, why clinicians should be concerned, and other information on Xylazine. Information about Xylazine is important to understand now that it has been showing up in illicit drug supply.